GSK Trelegy Ellipta 100/62.5/25 mcg – 30 Doses

Advanced Triple-Combination Maintenance Inhaler for COPD and Certain Adult Asthma Patients

Trelegy Ellipta is an advanced, once-daily prescription dry-powder inhaler manufactured by GlaxoSmithKline (GSK). It combines three active ingredients in one inhaler to support long-term management of specific chronic respiratory conditions.

Each inhalation contains three medicines:

• Fluticasone Furoate 100 mcg: An inhaled corticosteroid (ICS) that reduces inflammation in the airways.
• Umeclidinium 62.5 mcg: A long-acting muscarinic antagonist (LAMA) that helps relax airway muscles and keep airways open.
• Vilanterol 25 mcg: A long-acting beta-2 agonist (LABA) that helps relax airway muscles and improve airflow.

Key Product Features

• Genuine GSK Trelegy Ellipta branded prescription inhaler.
• Three active respiratory medicines combined in one device.
• Dry-powder inhalation delivery system.
• Once-daily maintenance treatment when prescribed.
• 30 measured inhalation doses per inhaler.
• Designed for long-term respiratory disease management.
• Convenient Ellipta inhaler with an integrated dose counter.

Pack Size: 1 inhaler
Total Doses: 30
Strength: 100 mcg / 62.5 mcg / 25 mcg
Product Type: Prescription-only medicine
Manufacturer: GlaxoSmithKline (GSK)
Market/Sourcing Description: Istanbul, Turkey (verify the actual country of manufacture and packaging before listing).

Why Doctors May Prescribe Trelegy Ellipta

1. Three-in-One Treatment: Combines an inhaled corticosteroid, a LAMA and a LABA in one inhaler.
2. Helps Reduce Airway Inflammation: Fluticasone furoate helps control inflammation inside the airways.
3. Helps Open the Airways: Umeclidinium and vilanterol work through different mechanisms to relax airway muscles.
4. Supports Breathing Management: Helps improve airflow and respiratory symptom control in appropriately selected patients.
5. COPD Maintenance Therapy: Used for long-term management of COPD in patients meeting the approved treatment criteria.
6. Adult Asthma Maintenance: Approved for certain adult asthma patients in some markets, depending on local product authorization.
7. Once-Daily Convenience: Designed for one inhalation once daily as prescribed.
8. Integrated Dose Counter: Helps patients monitor the remaining doses.

Important: Trelegy is a maintenance treatment, not an emergency inhaler. It does not provide immediate relief from sudden breathing difficulties.

Indications and Intended Users

Trelegy Ellipta may be prescribed by a qualified healthcare professional for:

1. Chronic Obstructive Pulmonary Disease (COPD)

A long-term respiratory condition involving persistent airflow limitation, including conditions such as chronic bronchitis and emphysema.

2. Selected Adult Asthma Patients

In countries where the relevant strength is approved for asthma, it may be prescribed for adults whose asthma is not adequately controlled with appropriate existing maintenance treatment.

3. Patients Requiring Triple-Inhaler Therapy

Patients whose respiratory symptoms or disease exacerbations are not adequately managed with certain dual-combination inhalers may be assessed by their physician for triple therapy.

Important: The appropriate indication, eligibility and treatment strength depend on the patient's diagnosis, medical history and the approved product information in the country of use. It is not suitable for everyone.